Table 3 Summary of the study population used in this work.
From: Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients
Total number of patients | 43 |
|---|---|
Male patients | 76.7% |
Response rate | 48.8% |
Median survival | 9.43 months |
Median time to progression | 5.5 months |
Median age | 64 years |
Range of age | 39-74 years |